Greenwich LifeSciences, Inc.
Market Cap
190M
Short interest (Jul 15)
10.0%
Net Short (Jul 27 ): 0.0%
Borrow Fee
43.22%
↓ 38.8%
Available Shares
200K
↓ 44.3%
Price Chart
Company Overview
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.